N-Substituted Benzyl Matrinic Acid Derivatives Inhibit Hepatitis C Virus (HCV) Replication through Down-Regulating Host Heat-Stress Cognate 70 (Hsc70) Expression

Heat-stress cognate 70 (Hsc70) is a host factor that helps hepatitis C virus (HCV) to complete its life cycle in infected hepatocytes. Using Hsc70 as a target for HCV inhibition, a series of novel N-substituted benzyl matrinic/sophoridinic acid derivatives was synthesized and evaluated for their anti-HCV activity in vitro. Among these analogues, compound 7c possessing N-p-methylbenzyl afforded an appealing ability to inhibit HCV replication with SI value over 53. Furthermore, it showed a good oral pharmacokinetic profile with area-under-curve (AUC) of 13.4 µM·h, and a considerably good safety in oral administration in mice (LD50>1000 mg/kg). As 7c suppresses HCV replication via an action mode distinctly different from that of the marketed anti-HCV drugs, it has been selected as a new mechanism anti-HCV candidate for further investigation, with an advantage of no or decreased chance to induce drug-resistant mutations.

[1]  Jian-Dong Jiang,et al.  Synthesis, structure-activity relationship and biological evaluation of novel N-substituted matrinic acid derivatives as host heat-stress cognate 70 (Hsc70) down-regulators. , 2011, Bioorganic & medicinal chemistry letters.

[2]  Jian-Dong Jiang,et al.  Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70. , 2011, Journal of medicinal chemistry.

[3]  Jian-Dong Jiang,et al.  Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA , 2010, Hepatology.

[4]  Valli De Re,et al.  Interferon-Based Therapy for Chronic Hepatitis C: Current and Future Perspectives , 2010, Hepatitis Monthly.

[5]  William M. Lee,et al.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.

[6]  Jean-Michel Pawlotsky,et al.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. , 2009, The New England journal of medicine.

[7]  F. S. Domingues,et al.  Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients , 2009, Hepatology.

[8]  I. Jacobson,et al.  New and experimental therapies for HCV , 2009, Nature Reviews Gastroenterology &Hepatology.

[9]  L. Beretta,et al.  The heat shock cognate protein 70 is associated with hepatitis C virus particles and modulates virus infectivity , 2009, Hepatology.

[10]  J. McHutchison,et al.  Antiviral resistance and specifically targeted therapy for HCV (STAT‐C) , 2009, Journal of viral hepatitis.

[11]  X. Tong,et al.  Identification of HCV protease inhibitor resistance mutations by selection pressure-based method , 2009, Nucleic acids research.

[12]  J. McHutchison,et al.  Review article: investigational agents for chronic hepatitis C , 2009, Alimentary pharmacology & therapeutics.

[13]  M. Manns,et al.  Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. , 2009, Current opinion in investigational drugs.

[14]  V. Soriano,et al.  New therapies for hepatitis C virus infection. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Todd M. Allen,et al.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.

[16]  S. A. Qureshi.  Hepatitis C virus—biology, host evasion strategies, and promising new therapies on the horizon , 2007, Medicinal research reviews.

[17]  S. A. Qureshi.  Hepatitis C virus—biology, host evasion strategies, and promising new therapies on the horizon , 2007, Medicinal research reviews.

[18]  Richard E. T. Smith.  Hepatitis C virus therapies , 2006, Nature Reviews Drug Discovery.

[19]  R. Focareta,et al.  From Trials to a Real Hospital Setting: Effectiveness of Pegylated Interferon-α-2b/Ribavirin Combination Therapy for Naïve Chronic Hepatitis C Patients , 2006, Digestive Diseases and Sciences.

[20]  A. Sadykov,et al.  Nmr investigation of the spatial structure of quinolizidine alkaloids IV. Conformation of sophoridine in solution , 1974, Chemistry of Natural Compounds.

[21]  A. Sadykov,et al.  Spatial structure of sophoridine and sophoridinic acid , 1968, Chemistry of Natural Compounds.

[22]  R. Hara,et al.  Studies on beta-lactam antibiotics. III. Syntheses and antibacterial activities of new 3-(1,3-dithiolan-2-yl)cephalosporins, YM-22508, YM-16457 and their prodrug-type esters. , 1991, The Journal of antibiotics.

[23]  R. Kelly,et al.  Total synthesis of .alpha.-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125), an antitumor antibiotic , 1979 .

[24]  H. Brown,et al.  Selective reductions. XVIII. Fast reaction of primary, secondary, and tertiary amides with diborane. Simple, convenient procedure for the conversion of amides to the corresponding amines , 1973 .

[25]  E. Ochiai,et al.  Synthesis of Matrine Derivatives. II. Studies on the Diazotization of Decarbonylmethylmatrinamine and the Ring-closure of Matrinic Acid Derivatives. , 1961 .